Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cybin Inc. (CYBN : AMEX)

• Company Description    Cybin Inc. is a biotechnology company. It is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin Inc. is based in Toronto, Canada. Number of Employees: 38

• Price / Volume Information    Yesterday's Closing Price: $0.57 Daily Weekly Monthly 20 Day Moving Average: 817,349 shares Shares Outstanding: 165.02 (millions) Market Capitalization: $94.06 (millions) Beta: 52 Week High: $3.38 52 Week Low: $0.39 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -21.92% -12.05% 12 Week -37.87% -31.69% Year To Date -52.50% -41.96%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 100 KING STREET WEST SUITE 5600 - TORONTO,A6 ON M5X 1C9 CAN ph: 908-764-8385 fax: - ir@cybin.com http://www.cybin.com

• General Corporate Information    Officers Doug Drysdale - Chief Executive Officer Eric So - Executive Chairman and President Greg Cavers - Chief Financial Officer John Kanakis - Chief Business Officer Gabe Fahel - Chief Legal Officer Peer Information Cybin Inc. (CORR.) Cybin Inc. (RSPI) Cybin Inc. (CGXP) Cybin Inc. (BGEN) Cybin Inc. (GTBP) Cybin Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 23256X100 SIC: 6770 Fiscal Year Fiscal Year End: March Last Reported Quarter: 12/01/21 Next Expected EPS Date: 06/27/22 Share - Related Items Shares Outstanding: 165.02 Most Recent Split Date: (:1) Beta: Market Capitalization: $94.06 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.08 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.31 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 06/27/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.32 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -14.29% vs. Previous Quarter: 11.11% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - - 12/31/21 - -71.99 09/30/21 - -72.84 ROA 03/31/22 - - 12/31/21 - -67.25 09/30/21 - -67.09 Current Ratio 03/31/22 - - 12/31/21 - 11.40 09/30/21 - 13.92 Quick Ratio 03/31/22 - - 12/31/21 - 11.40 09/30/21 - 13.92 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - - 12/31/21 - 0.43 09/30/21 - 0.49 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - - 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©